Thyme Care’s $125M Series E: Oncology Navigation Clears $2B With Payer Capital
Morgan Health led Thyme Care’s $125M+ Series E above a $2B valuation — Humana, CVS Health Ventures, AlleyCorp, and a16z Bio + Health joined as the company spins up Thyme Companies for biosimilars and trial access.